| Literature DB >> 33989106 |
Yongliang Feng1,2, Jianmin Wang3, Zhihong Shao1, Zhuanzhuan Chen1,2, Tian Yao1,2, Shuang Dong1,2, Yuanting Wu1,2, Xiaohong Shi1,2, Jing Shi1,2, Guangming Liu4, Jingen Bai5, Hongping Guo6, Hongting Liu7, Xiaofeng Wu8, Liming Liu3, Xiaohui Song9, Jiangtao Zhu10, Suping Wang1,2, Xiaofeng Liang11.
Abstract
The non/hypo-response rate of the hepatitis B vaccine among hemodialysis (HD) patients is still high, it is of great significance to explore the influencing factors and their relationships. To study the related factors and their relationships using logistic regression model and Chi-squared Automatic Interaction Detection (CHAID) decision tree model. A randomized controlled trial was conducted between February 2014 and May 2015 in China. HD patients being serologically negative for HBsAg and anti-HBs were randomly assigned to receive three intramuscular injections of the standard dose (20 µg) or high dose (60 µg) of recombinant hepatitis B vaccine at months 0, 1, and 6. Those with anti-HBs concentrations <100 mIU/mL, and ≥100 mIU/mL at month 7 were considered as non/hypo-response and high-level response, respectively. The non/hypo-response was 31.34% (89/284). After adjustment for confounders, logistic analysis showed that males (OR = 2.203, 95%CI: 1.109-4.367) and those with higher dialysis frequency (>4 times per 2 weeks) (OR = 1.918, 95%CI: 1.015-3.626) had a significant risk of non/hypo-response. While the CHAID analysis showed that gender, dose, and dialysis frequency were influencing factors of non/hypo-response, and gender is most important. The interaction between gender and dialysis frequency had the greatest effect on immunization, and followed by the interaction between dialysis frequency and vaccine dose. Taken together, gender, dose and dialysis frequency were influencing factors of hepatitis B vaccine in HD patients.Entities:
Keywords: Chi-squared automatic interaction detection; Hepatitis B vaccine; hemodialysis; logistic regression model; non/hypo-response
Mesh:
Substances:
Year: 2021 PMID: 33989106 PMCID: PMC8381824 DOI: 10.1080/21645515.2021.1895603
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452